文献速递技术与安全胸部腹部

免疫检查点抑制剂肿瘤治疗:影像表现谱

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
PubMed 文献 · Radiographics · 2017-01-01

免疫检查点抑制剂自2011年获批用于晚期黑色素瘤后临床应用迅速增加,适应证还包括非小细胞肺癌、头颈鳞癌、肾细胞癌、尿路上皮癌和经典型霍奇金淋巴瘤。部分患者出现假性进展,即治疗后新发或增大的病灶随后总肿瘤负荷下降,传统疗效标准在肿瘤负荷初次增加时会将之误判为治疗失败,目前仅随访影像可帮助鉴别。此外该类药物的独特机制可引起与自身免疫相关的严重或危及生命的不良事件。

要点

  • 免疫检查点抑制剂治疗后新发或增大的病灶可能为假性进展,随访影像可帮助与真性进展鉴别。
  • 在肿瘤负荷初次增加时套用传统疗效标准会将假性进展误判为治疗失败,可能导致不恰当地终止治疗。
  • 免疫检查点抑制剂可引起与自身免疫相关的、可严重或危及生命的不良事件,影像对及时诊断有重要作用。

核心结论

  • 免疫检查点抑制剂治疗后新发或增大的病灶,目前只有随访影像能帮助区分假性进展与占大多数的真性治疗失败;放射科医生需熟悉该类药物的作用机制以正确评估疗效并及时诊断治疗相关并发症。

研究设计与样本

  • 综述;作者复习免疫检查点抑制剂的分子机制与临床应用、目前区分假性进展与进展的策略,以及常见免疫相关不良事件的影像表现。

诊断标准与关键数值

  • 假性进展:治疗开始后出现新发或增大的病灶, mimicking 肿瘤进展,随后总肿瘤负荷最终下降。
  • 传统疗效标准在肿瘤负荷初次增加时应用,可将假性进展错误判定为治疗失败。
  • 目前仅随访影像可帮助区分假性进展与真性治疗失败。

临床应用与阅片要点

  • 放射科医生应了解免疫检查点抑制剂,以正确评估治疗反应并及时诊断治疗相关并发症。
  • 观察到新发或增大的病灶时,随访影像是目前区分假性进展与真性进展的手段。

局限性

  • 目前只有随访影像能帮助区分假性进展与真性治疗失败。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Immune checkpoint inhibitors are a new class of cancer therapeutics that have demonstrated striking successes in a rapid series of clinical trials. Consequently, these drugs have dramatically increased in clinical use since being first approved for advanced melanoma in 2011. Current indications in addition to melanoma are non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, and classical Hodgkin lymphoma. A small subset of patients treated with immune checkpoint inhibitors undergoes an atypical treatment response pattern termed pseudoprogression: New or enlarging lesions appear after initiation of therapy, thereby mimicking tumor progression, followed by an eventual decrease in total tumor burden. Traditional response standards applied at the time of initial increase in tumor burden can falsely designate this as treatment failure and could lead to inappropriate termination of therapy. Currently, when new or enlarging lesions are observed with immune checkpoint inhibitors, only follow-up imaging can help distinguish patients with pseudoprogression from the large majority in whom this observation represents true treatment failure. Furthermore, the unique mechanism of immune checkpoint inhibitors can cause a distinct set of adverse events related to autoimmunity, which can be severe or life threatening. Given the central role of imaging in cancer care, radiologists must be knowledgeable about immune checkpoint inhibitors to correctly assess treatment response and expeditiously diagnose treatment-related complications. The authors review the molecular mechanisms and clinical applications of immune checkpoint inhibitors, the current strategy to distinguish pseudoprogression from progression, and the imaging appearances of common immune-related adverse events. ©RSNA, 2017.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Wang GX, Kurra V, Gainor JF, et al. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics. 2017. PMID: 29131763. doi:10.1148/rg.2017170085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。